Edwards strikes $690M deal to buy Valtech Cardio

« Back to Industry News

30/11/2016

Edwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year. The new agreement will see Edwards pay $340 million in stock and cash upfront aEdwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year. The new agreement will see Edwards pay $340 million in stock and cash upfront and up to $350 million in milestones to acquire Valtech and its system for transcatheter repair of the mitral and tricuspid valves.

“We saw an important opportunity to incorporate Valtech's technologies into our comprehensive heart valve repair and replacement portfolio," Edwards CEO Michael Mussallem said in a statement. "We recognize that physicians will likely need a toolbox of options to treat their patients most effectively.” Mussallem sees the pairing of Valtech's Cardioband and Edwards’ own programs giving the company such a toolbox.


Click here to view the full related article.

« Back to Industry News